This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

PRISMS study

Authoring team

The Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) was a double-blind, placebo-controlled trial of interferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Patients had mild to moderate multiple sclerosis (EDSS scores 0 - 5.0).

Patients were randomised to 2 years of:

  • placebo
  • 22 mcg subcutaneously three times per week
  • 44 mcg subcutaneously three times pre week

Reference:

  • 1) PRISMS Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352(7), 1498-504

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.